Format

Send to

Choose Destination
Haematologica. 2017 May;102(5):903-909. doi: 10.3324/haematol.2016.154377. Epub 2017 Jan 25.

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.

Author information

1
Institut de Cancérologie Gustave Roussy, Villejuif, France vincent.ribrag@gustaveroussy.fr.
2
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
3
CLCC Institut Paoli Calmettes, Marseille, France.
4
National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore.
5
Hospices Civils de Lyon, France.
6
Department of Hematology, Faculty of Medicine, University of Debrecen Medical and Health Science Center, Hungary.
7
CHUM, Montreal, QC, Canada.
8
Ernest and Helen Scott Haematological Research Institute, University of Leicester, UK.
9
Universitair Ziekenhuis Gent, Gent, Belgium.
10
Servier, Paris, France.
11
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
12
Department of Hematology, Université de Lille, EA GRIIOT, France.

Abstract

Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved inhibitors; its unique pharmacokinetic profile and oral dosing schedule, twice daily four hours apart, allows for continuous exposure at concentrations required to efficiently kill tumor cells. In this phase II study, patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia received oral abexinostat at 80 mg BID for 14 days of a 21-day cycle and continued until progressive disease or unacceptable toxicity. A total of 100 patients with B-cell malignancies and T-cell lymphomas were enrolled between October 2011 and July 2014. All patients received at least one dose of study drug. Primary reasons for discontinuation included progressive disease (56%) and adverse events (25%). Grade 3 or over adverse events and any serious adverse events were reported in 88% and 73% of patients, respectively. The most frequently reported grade 3 or over treatment-emergent related adverse events were thrombocytopenia (80%), neutropenia (27%), and anemia (12%). Among the 87 patients evaluable for efficacy, overall response rate was 28% (complete response 5%), with highest responses observed in patients with follicular lymphoma (overall response rate 56%), T-cell lymphoma (overall response rate 40%), and diffuse large B-cell lymphoma (overall response rate 31%). Further investigation of the safety and efficacy of abexinostat in follicular lymphoma, T-cell lymphoma, and diffuse large B-cell lymphoma implementing a less dose-intense week-on-week-off schedule is warranted. (Trial registered at: EudraCT-2009-013691-47).

PMID:
28126962
PMCID:
PMC5477609
DOI:
10.3324/haematol.2016.154377
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center